Further research indicated that the growth of MC38 tumors can be effectively suppressed by intratumoral treatment with the STING agonist 3’3’-cGAMP leading to enhanced intratumoral infiltration and activation of CD8+ T cells (124), suggesting that the ability of STING to suppress tumor growth may rely on regulating immune cells and the activation of STING could be a therapeutic strategy for CRC treatment. This evidence concerns the gene CD8A and neoplasm.